Corbus Pharmaceuticals Holdings, Inc. Stock
Equities
CRBP
US21833P3010
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
41.93 USD | -2.47% | +8.01% | +594.21% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 3.33M | Capitalization | 452M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -69M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 136 x |
P/E ratio 2024 * |
-7.34
x | P/E ratio 2025 * |
-7.41
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.32% |
Latest transcript on Corbus Pharmaceuticals Holdings, Inc.
1 day | -1.71% | ||
1 week | +10.88% | ||
Current month | +16.06% | ||
1 month | +5.24% | ||
3 months | +86.91% | ||
6 months | +1,222.77% | ||
Current year | +611.75% |
Managers | Title | Age | Since |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 14-04-10 |
Chief Tech/Sci/R&D Officer | 50 | Feb. 27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 13-12-31 |
Avery Catlin
BRD | Director/Board Member | 75 | 14-07-31 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 41.93 | -2.47% | 61 001 |
24-05-10 | 42.99 | -1.71% | 92,145 |
24-05-09 | 43.74 | +3.18% | 650,385 |
24-05-08 | 42.39 | +6.59% | 779,421 |
24-05-07 | 39.77 | +2.45% | 160,195 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+611.75% | 452M | |
+3.91% | 109B | |
+10.87% | 105B | |
+0.17% | 22.25B | |
-13.14% | 22.09B | |
-7.87% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CRBP Stock